Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Cedar Pollen Allergy-Pipeline Review, H1 2015

Cedar Pollen Allergy-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Cedar Pollen Allergy-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cedar Pollen Allergy-Pipeline Review, H1 2015', provides an overview of the Cedar Pollen Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Cedar Pollen Allergy Overview 7

Therapeutics Development 8

Pipeline Products for Cedar Pollen Allergy-Overview 8

Pipeline Products for Cedar Pollen Allergy-Comparative Analysis 9

Cedar Pollen Allergy-Therapeutics under Development by Companies 10

Cedar Pollen Allergy-Therapeutics under Investigation by Universities/Institutes 11

Cedar Pollen Allergy-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Cedar Pollen Allergy-Products under Development by Companies 14

Cedar Pollen Allergy-Products under Investigation by Universities/Institutes 15

Cedar Pollen Allergy-Companies Involved in Therapeutics Development 16

Allergy Therapeutics plc 16

Anergis SA 17

Biomay AG 18

Circassia Pharmaceuticals plc 19

Immunomic Therapeutics, Inc. 20

Japan Tobacco Inc. 21

REGiMMUNE Corporation 22

Stallergenes S.A. 23

Cedar Pollen Allergy-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

AllerJ-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ASP-4070-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Drugs for Cedar Pollen Allergy-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Japanese cedar hypoallergenic vaccine-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

JCC-LAMP-Vax-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

MC-LAMP-Vax-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Pollinex Quattro Japanese Cedar-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

RGI-1001-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

STG-120-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

TO-206-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Vaccine for Cedar Pollen Allergy-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Vaccine for Cedar Pollen Allergy-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Cedar Pollen Allergy-Recent Pipeline Updates 44

Cedar Pollen Allergy-Dormant Projects 46

Cedar Pollen Allergy-Dormant Projects 46

Cedar Pollen Allergy-Product Development Milestones 47

Featured News & Press Releases 47

Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference 47

Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting 47

Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy 48

Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy 48

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51

List of Tables

Number of Products under Development for Cedar Pollen Allergy, H1 2015 8

Number of Products under Development for Cedar Pollen Allergy-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Products under Investigation by Universities/Institutes, H1 2015 15

Cedar Pollen Allergy-Pipeline by Allergy Therapeutics plc, H1 2015 16

Cedar Pollen Allergy-Pipeline by Anergis SA, H1 2015 17

Cedar Pollen Allergy-Pipeline by Biomay AG, H1 2015 18

Cedar Pollen Allergy-Pipeline by Circassia Pharmaceuticals plc, H1 2015 19

Cedar Pollen Allergy-Pipeline by Immunomic Therapeutics, Inc., H1 2015 20

Cedar Pollen Allergy-Pipeline by Japan Tobacco Inc., H1 2015 21

Cedar Pollen Allergy-Pipeline by REGiMMUNE Corporation, H1 2015 22

Cedar Pollen Allergy-Pipeline by Stallergenes S.A., H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Stage and Target, H1 2015 25

Number of Products by Stage and Route of Administration, H1 2015 27

Number of Products by Stage and Molecule Type, H1 2015 29

Cedar Pollen Allergy Therapeutics-Recent Pipeline Updates, H1 2015 44

Cedar Pollen Allergy-Dormant Projects, H1 2015 46

List of Figures

Number of Products under Development for Cedar Pollen Allergy, H1 2015 8

Number of Products under Development for Cedar Pollen Allergy-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Top 10 Routes of Administration, H1 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27

Number of Products by Top 10 Molecule Types, H1 2015 28

Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Allergy Therapeutics plc

Anergis SA

Biomay AG

Circassia Pharmaceuticals plc

Immunomic Therapeutics, Inc.

Japan Tobacco Inc.

REGiMMUNE Corporation

Stallergenes S.A.

Cedar Pollen Allergy Therapeutic Products under Development, Key Players in Cedar Pollen Allergy Therapeutics, Cedar Pollen Allergy Pipeline Overview, Cedar Pollen Allergy Pipeline, Cedar Pollen Allergy Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com